Bernstein analyst Lee Hambright raised the firm’s price target on Abbott (ABT) to $138 from $135 and keeps an Outperform rating on the shares following a good quarter. Investors have worried about Abbott’s delay in getting a PFA product to market, but EP continues to perform better than expected based on strength in mapping.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABT:
- Abbott price target raised to $148 from $146 at UBS, shares remain undervalued
- Abbott Laboratories Reports Strong 2024 Financial Results
- Abbott price target raised to $140 from $139 at BTIG
- Netflix, Seagate, J&J report quarterly beats: Morning Buzz
- ABT Earnings: Abbott Posts Mixed Q4 Results, Issues FY25 Growth Outlook